Skip to main content

Eli Lilly on track to close with a higher market cap than J&J for first time since 1997

Eli Lilly's stock has benefited from positive data in trials of an obesity drug and a treatment for Alzheimer's disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.